This Article  • References  • Full text PDF  • Reply to article  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citing articles on HighWire  • Contact me when this article is cited  Related Content  • Similar articles in this journal  Social Bookmarking   What's this?

George J. Brewer, MD
Department of Human Genetics University of Michigan 4708 Medical Science IIM4708 Ann Arbor, MI 48109-0618

Arch Neurol. 1992;49(2):132-133.

	Since this article does not have an abstract, we have provided the first 150 words of the full text PDF and any section headings.

In Reply.

—We wish to respond to the letter by Walshe, who made important contributions to the therapy of Wilson's disease 35 and 22 years ago, with the introduction of penicillamine and trien, respectively, in peer-reviewed journal articles.^1,2 In response to our recent article³ on the use of ammonium tetrathiomolybdate (TM) for the initial treatment of neurologically ill patients with Wilson's disease published in the ARCHIVES, Walshe complains about a number of areas.

First, Walshe will be pleased to know that we were not "unaware" of the literature that he mentions, but felt that it was not sufficiently relevant to the topic of our article to be included in the reference list. Four references on the previous knowledge of the anticopper effect of TM were given (references 6 through 9,³ dating back to 1981). We note that the interesting history of how TM came to be known . . . [Full Text PDF of this Article]

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?